Enhancement of the Anti-tumor Activity of Recombinant Interleukin-2 (rIL-2) by Immunocomplexing with an F (ab')2 Fragment of Murine Monoclonal Antibody against rIL-2

We have investigated the biological properties of an immune complex composed of recombinant interleukin-2 (rIL-2) and an F (ab')2 fragment of a monoclonal antibody against rIL-2 in mice for the induction of killer cells and anti-tumor activity, as well as the pharmacokinetic properties of the i...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 1994/08/15, Vol.17(8), pp.1101-1105
Main Authors: SATO, Jun, HAMAGUCHI, Naoru, DOKEN, Kazuhiro, GOTOH, Kazunori, OOTSU, Koichiro, IWASA, Susumu, OGAWA, Yasuaki, TOGUCHI, Hajime
Format: Article
Language:English
Subjects:
Animals
anti-tumor effect
Antibodies, Monoclonal - immunology
Antineoplastic agents
Antineoplastic Agents - pharmacology
Biological and medical sciences
Cell Division - drug effects
Cell Survival - drug effects
Enzyme-Linked Immunosorbent Assay
F (ab')2 fragment immune complex
Female
Fibrosarcoma - drug therapy
Immunoglobulin Fab Fragments - pharmacology
Immunoglobulin G - immunology
Immunotherapy
Interleukin-2 - pharmacology
Killer Cells, Lymphokine-Activated - drug effects
Medical sciences
Mice
Mice, Inbred BALB C
monoclonal antibody
pharmacokinetics
Pharmacology. Drug treatments
recombinant interleukin-2
Recombinant Proteins - pharmacology
Tumor Cells, Cultured
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have investigated the biological properties of an immune complex composed of recombinant interleukin-2 (rIL-2) and an F (ab')2 fragment of a monoclonal antibody against rIL-2 in mice for the induction of killer cells and anti-tumor activity, as well as the pharmacokinetic properties of the immune complex injected subcutaneous-ly into mice. The immune complex demonstrated sustained serum rIL-2 levels, with a 2.4-times longer"mean-residence-time"than free rIL-2. A more significant portion of rIL-2 was detected in lymph nodes after the subcutaneous injection of the immune complex than with rIL-2 alone. Splenic lymphocytes from mice given the immune complex showed higher killer cell activity against YAC-1 and P815 cells than those from mice given rIL-2 alone. The immune complex also exerted a more significant anti-tumor effect in a dose-dependent manner in Meth-A fibrosarcoma-bearing mice than dit rIL-2 alone.
ISSN:0918-6158
1347-5215
DOI:10.1248/bpb.17.1101